Home / Resource Library / A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Results of a phase II study investigating Camrelizumab for treatment of relapsed Hodgkin lymphoma.